SKYE
Price
$2.08
Change
-$0.13 (-5.88%)
Updated
May 22, 04:59 PM (EDT)
Capitalization
68.48M
SLDB
Price
$2.89
Change
+$0.19 (+7.04%)
Updated
May 22, 04:59 PM (EDT)
Capitalization
228.67M
Interact to see
Advertisement

SKYE vs SLDB

Header iconSKYE vs SLDB Comparison
Open Charts SKYE vs SLDBBanner chart's image
Skye Bioscience
Price$2.08
Change-$0.13 (-5.88%)
Volume$1.16K
Capitalization68.48M
Solid Biosciences
Price$2.89
Change+$0.19 (+7.04%)
Volume$119.49K
Capitalization228.67M
SKYE vs SLDB Comparison Chart
Loading...
SKYE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SKYE vs. SLDB commentary
May 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SKYE is a Hold and SLDB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 22, 2025
Stock price -- (SKYE: $2.21 vs. SLDB: $2.70)
Brand notoriety: SKYE and SLDB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SKYE: 26% vs. SLDB: 95%
Market capitalization -- SKYE: $68.48M vs. SLDB: $228.67M
SKYE [@Biotechnology] is valued at $68.48M. SLDB’s [@Biotechnology] market capitalization is $228.67M. The market cap for tickers in the [@Biotechnology] industry ranges from $305.18B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SKYE’s FA Score shows that 0 FA rating(s) are green whileSLDB’s FA Score has 2 green FA rating(s).

  • SKYE’s FA Score: 0 green, 5 red.
  • SLDB’s FA Score: 2 green, 3 red.
According to our system of comparison, SLDB is a better buy in the long-term than SKYE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SKYE’s TA Score shows that 5 TA indicator(s) are bullish while SLDB’s TA Score has 4 bullish TA indicator(s).

  • SKYE’s TA Score: 5 bullish, 3 bearish.
  • SLDB’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, SKYE is a better buy in the short-term than SLDB.

Price Growth

SKYE (@Biotechnology) experienced а +16.32% price change this week, while SLDB (@Biotechnology) price change was +5.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.02%. For the same industry, the average monthly price growth was +7.66%, and the average quarterly price growth was -1.31%.

Reported Earning Dates

SKYE is expected to report earnings on Mar 20, 2025.

SLDB is expected to report earnings on Mar 06, 2025.

Industries' Descriptions

@Biotechnology (+5.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SLDB($229M) has a higher market cap than SKYE($68.5M). SKYE YTD gains are higher at: -21.908 vs. SLDB (-32.500). SKYE has higher annual earnings (EBITDA): -31.66M vs. SLDB (-121.9M). SLDB has more cash in the bank: 149M vs. SKYE (59.2M). SKYE has less debt than SLDB: SKYE (412K) vs SLDB (24.2M). SKYE (0) and SLDB (0) have equivalent revenues.
SKYESLDBSKYE / SLDB
Capitalization68.5M229M30%
EBITDA-31.66M-121.9M26%
Gain YTD-21.908-32.50067%
P/E Ratio3.57N/A-
Revenue00-
Total Cash59.2M149M40%
Total Debt412K24.2M2%
FUNDAMENTALS RATINGS
SKYE vs SLDB: Fundamental Ratings
SKYE
SLDB
OUTLOOK RATING
1..100
7310
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
19
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6465
P/E GROWTH RATING
1..100
982
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLDB's Valuation (19) in the Biotechnology industry is in the same range as SKYE (35) in the null industry. This means that SLDB’s stock grew similarly to SKYE’s over the last 12 months.

SLDB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SKYE (100) in the null industry. This means that SLDB’s stock grew similarly to SKYE’s over the last 12 months.

SLDB's SMR Rating (100) in the Biotechnology industry is in the same range as SKYE (100) in the null industry. This means that SLDB’s stock grew similarly to SKYE’s over the last 12 months.

SKYE's Price Growth Rating (64) in the null industry is in the same range as SLDB (65) in the Biotechnology industry. This means that SKYE’s stock grew similarly to SLDB’s over the last 12 months.

SLDB's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for SKYE (98) in the null industry. This means that SLDB’s stock grew significantly faster than SKYE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SKYESLDB
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
78%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
85%
MACD
ODDS (%)
Bullish Trend 7 days ago
79%
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 11 days ago
86%
Bullish Trend 3 days ago
79%
Declines
ODDS (%)
Bearish Trend 9 days ago
90%
Bearish Trend 9 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
SKYE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLDB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MEFOX60.45N/A
N/A
Meehan Focus
FGIPX15.34N/A
N/A
Macquarie Growth and Income Instl
PWJDX33.86N/A
N/A
PGIM Jennison International Opps R4
RISRX13.11N/A
N/A
RBC International Small Cap Equity R6
BBMIX11.22-0.33
-2.86%
BBH Select Series - Mid Cap I

SKYE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SKYE has been loosely correlated with CRBP. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if SKYE jumps, then CRBP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SKYE
1D Price
Change %
SKYE100%
+12.18%
CRBP - SKYE
49%
Loosely correlated
-2.11%
JANX - SKYE
40%
Loosely correlated
-2.48%
VKTX - SKYE
34%
Loosely correlated
-4.95%
PGEN - SKYE
31%
Poorly correlated
-6.38%
SLDB - SKYE
31%
Poorly correlated
-8.47%
More

SLDB and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLDB has been loosely correlated with BEAM. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if SLDB jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLDB
1D Price
Change %
SLDB100%
-8.47%
BEAM - SLDB
49%
Loosely correlated
-2.99%
NTLA - SLDB
47%
Loosely correlated
-4.86%
ALLO - SLDB
46%
Loosely correlated
-4.31%
EDIT - SLDB
46%
Loosely correlated
-8.54%
RCKT - SLDB
45%
Loosely correlated
-3.80%
More